192 related articles for article (PubMed ID: 25111485)
21. Differential methylation hybridization array of endometrial cancers reveals two novel cancer-specific methylation markers.
Zighelboim I; Goodfellow PJ; Schmidt AP; Walls KC; Mallon MA; Mutch DG; Yan PS; Huang TH; Powell MA
Clin Cancer Res; 2007 May; 13(10):2882-9. PubMed ID: 17504987
[TBL] [Abstract][Full Text] [Related]
22. [Detection of free tumor-related DNA in the serum of breast cancer patients].
Zhang JJ; Ouyang T; Wan WH; Deng GR
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):609-13. PubMed ID: 18210882
[TBL] [Abstract][Full Text] [Related]
23. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse.
Noetzel E; Rose M; Sevinc E; Hilgers RD; Hartmann A; Naami A; Knüchel R; Dahl E
Oncogene; 2010 Aug; 29(34):4814-25. PubMed ID: 20543860
[TBL] [Abstract][Full Text] [Related]
24. Innovative biomarker development for personalized medicine in breast cancer care.
Zografos GC; Roukos DH
Biomark Med; 2011 Feb; 5(1):73-8. PubMed ID: 21319967
[No Abstract] [Full Text] [Related]
25. Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis.
Faryna M; Konermann C; Aulmann S; Bermejo JL; Brugger M; Diederichs S; Rom J; Weichenhan D; Claus R; Rehli M; Schirmacher P; Sinn HP; Plass C; Gerhauser C
FASEB J; 2012 Dec; 26(12):4937-50. PubMed ID: 22930747
[TBL] [Abstract][Full Text] [Related]
26. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients.
Sharma G; Mirza S; Prasad CP; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Apr; 80(20):1873-81. PubMed ID: 17383681
[TBL] [Abstract][Full Text] [Related]
27. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
[TBL] [Abstract][Full Text] [Related]
28. DNA methylation as a biomarker in breast cancer.
Martens JW; Margossian AL; Schmitt M; Foekens J; Harbeck N
Future Oncol; 2009 Oct; 5(8):1245-56. PubMed ID: 19852739
[TBL] [Abstract][Full Text] [Related]
29. DNA-based assay for EPHB6 expression in breast carcinoma cells as a potential diagnostic test for detecting tumor cells in circulation.
Fox BP; Kandpal RP
Cancer Genomics Proteomics; 2010; 7(1):9-16. PubMed ID: 20181626
[TBL] [Abstract][Full Text] [Related]
30. Bisulfite-modified target DNA array for aberrant methylation analysis.
Zhou D; Qiao W; Yang L; Lu Z
Anal Biochem; 2006 Apr; 351(1):26-35. PubMed ID: 16516134
[TBL] [Abstract][Full Text] [Related]
31. Identification of breast cancer DNA methylation markers optimized for fine-needle aspiration samples.
Bu D; Lewis CM; Sarode V; Chen M; Ma X; Lazorwitz AM; Rao R; Leitch M; Moldrem A; Andrews V; Gazdar A; Euhus D
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2212-21. PubMed ID: 24089458
[TBL] [Abstract][Full Text] [Related]
32. Detection of TFPI2 methylation in the serum of colorectal cancer patients.
Hibi K; Goto T; Shirahata A; Saito M; Kigawa G; Nemoto H; Sanada Y
Cancer Lett; 2011 Dec; 311(1):96-100. PubMed ID: 21820798
[TBL] [Abstract][Full Text] [Related]
33. Challenges for biomarkers in cancer detection.
Wagner PD; Verma M; Srivastava S
Ann N Y Acad Sci; 2004 Jun; 1022():9-16. PubMed ID: 15251933
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation biomarkers in cancer: progress towards clinical implementation.
Mikeska T; Bock C; Do H; Dobrovic A
Expert Rev Mol Diagn; 2012 Jun; 12(5):473-87. PubMed ID: 22702364
[TBL] [Abstract][Full Text] [Related]
35. The clinical potential and challenges of sequencing cancer genomes for personalized medical genomics.
Cloonan N; Waddell N; Grimmond SM
IDrugs; 2010 Nov; 13(11):778-81. PubMed ID: 21046525
[TBL] [Abstract][Full Text] [Related]
36. The path to personalized medicine in women's cancers: challenges and recent advances.
Konecny GE
Curr Opin Obstet Gynecol; 2015 Feb; 27(1):45-7. PubMed ID: 25517359
[No Abstract] [Full Text] [Related]
37. Molecular tests for colorectal cancer screening.
Bosch LJ; Carvalho B; Fijneman RJ; Jimenez CR; Pinedo HM; van Engeland M; Meijer GA
Clin Colorectal Cancer; 2011 Mar; 10(1):8-23. PubMed ID: 21609931
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic profiling joins personalized cancer medicine.
Heyn H; Méndez-González J; Esteller M
Expert Rev Mol Diagn; 2013 Jun; 13(5):473-9. PubMed ID: 23782254
[TBL] [Abstract][Full Text] [Related]
39. Dysplasia and cancer screening in 21st century.
Khunger M; Kumar U; Roy HK; Tiwari AK
APMIS; 2014 Aug; 122(8):674-82. PubMed ID: 24910362
[TBL] [Abstract][Full Text] [Related]
40. Improving early breast cancer detection: focus on methylation.
Suijkerbuijk KPM; van Diest PJ; van der Wall E
Ann Oncol; 2011 Jan; 22(1):24-29. PubMed ID: 20591821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
